National Pharmaceutical Council Welcomes Mallinckrodt as Its Newest Member

(Washington, D.C., June 23, 2016) –The National Pharmaceutical Council (NPC) today announced that Mallinckrodt Pharmaceuticals has joined the health policy research organization as its newest member.

Steven Romano, MD, senior vice president and chief scientific officer, Mallinckrodt Pharmaceuticals, will serve as his company’s representative on the NPC Board of Directors.

“We are pleased that Mallinckrodt has joined us in support of our efforts to conduct research and educational activities on important health policy issues such as real-world evidence, how heath care is valued and accessed, and biopharmaceutical innovation,“ said NPC President Dan Leonard. “We welcome Dr. Romano’s expertise on our Board and are looking forward to his involvement with NPC.”

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.

In becoming an NPC member, Mallinckrodt joins with other leading research-based biopharmaceutical companies, including AbbVie, Allergan, Inc., Amgen, Inc., Astellas Pharma US, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals, Biogen, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, Purdue Pharma, Sanofi, Takeda Pharmaceuticals USA, Inc., and Teva Pharmaceuticals.

About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit and follow NPC on Twitter @npcnow.